Open AccessSTARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma
Author(s) -
Dirk Schadendorf,
Reinhard Dummer,
Caroline Robert,
Antoni Ribas,
Ryan J. Sullivan,
Timothy Panella,
Meredith McKean,
Edgardo S. Santos,
Kimberli J. Brill,
Anna Polli,
Alessandra di Pietro,
Paolo A. Ascierto
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1486
Subject(s) - pembrolizumab , medicine , targeted therapy , immunotherapy , oncology , melanoma , trametinib , metastatic melanoma , clinical trial , combination therapy , cancer research , cancer , mapk/erk pathway , kinase , microbiology and biotechnology , biology
Despite the significant progress in the treatment of unresectable or metastatic BRAF V600-mutant melanoma, there remains two primary treatment options: targeted therapy and immunotherapy. Targeted therapy or immunotherapy alone is associated with efficacy limitations including efficacy limited to select patient subsets. With separate mechanisms of action and different response patterns, the combination of targeted agents and immunotherapy to treat patients with BRAF V600-mutant melanoma may further improve patient outcomes. Current treatment guidelines recommend treatment with targeted agents alone, immunotherapy, or the combination of targeted agents and immunotherapy. The randomized, double-blind STARBOARD trial aims to evaluate efficacy and safety of encorafenib, binimetinib, and pembrolizumab in treatment-naive patients with metastatic or unresectable locally advanced BRAF V600-mutant melanoma in comparison to pembrolizumab.